These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21654145)

  • 1. An unusual recurrence of antitubercular drug induced hepatotoxicity in a child.
    Bhatia S; Tullu MS; Kannan S; Gogtay NJ; Thatte UM; Lahiri KR
    J Postgrad Med; 2011; 57(2):147-52. PubMed ID: 21654145
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liver damage from tuberculosis treatment].
    Keiner F
    Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of isoniazid in hepatotoxicity with the INH-rifampicin combination in tuberculosis in children].
    Dieu MJ
    J Med Lyon; 1972 Oct; 53(234):1323-4 passim. PubMed ID: 4539047
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid].
    Xing T; Chen J; Zhang G
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Feb; 20(1):33-5. PubMed ID: 10072800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D; Macdonald L
    CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract]   [Full Text] [Related]  

  • 10. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 11. [Monitoring of antitubercular treatments. Value of the determination of serum gamma-glutamyl transpeptidase (gamma-GT)].
    Homasson JP; Salignac P; Bonniot JP; Parent G; Angebault M
    Nouv Presse Med; 1977 Mar; 6(10):858. PubMed ID: 15237
    [No Abstract]   [Full Text] [Related]  

  • 12. [Toxicity in the current treatment of pulmonary tuberculosis in children].
    Altet Gómez MN; Alcáide Megías J; Boque Genovard MA
    An Esp Pediatr; 1984 Jan; 20(1):18-27. PubMed ID: 6230974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 14. Isoniazid and rifampicin rarely cause acute pancreatitis in patients with tuberculosis.
    Chan TY
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):109. PubMed ID: 10082175
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
    Ozick LA; Jacob L; Comer GM; Lee TP; Ben-Zvi J; Donelson SS; Felton CP
    Am J Gastroenterol; 1995 Nov; 90(11):1978-80. PubMed ID: 7485004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitubercular drug-induced liver injuries].
    Guo Y; Cui D
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
    [No Abstract]   [Full Text] [Related]  

  • 17. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hydrazide-rifampicin: hepatotoxicity in children].
    Uriz Urzainqui S; Masvidal Aliberch RM; Sabriá Pau J; Bofill Bernaldo AM
    An Esp Pediatr; 1981 Oct; 15(4):401-3. PubMed ID: 7337305
    [No Abstract]   [Full Text] [Related]  

  • 20. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.